First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

作者：Lin Wang, Xuezhi Hao, Yanrong Hao, Yanping Hu, Chun Chen, Bi Chen, Yunchao Huang, Aimin Zang, Yan Wang, Zhendong Chen, Wu Zhuang, Jinsheng Shi, Xiubao Ren, Ligong Nie, Guohua Yu, Feng Luo, Yimin Mao, Xiang Wang, Baolan Li, Yuansong Bai, Jianhua Shi, Hongyan Ni, Haoyu Yu, Jing Li, Qingyu Wang, Junwu Zhu, Yuankai Shi, Kejing Ying, Guoping Sun, Jinsheng Wu, Chuan Jin, Lin H. Lin, Xingya Li, Hongmei Sun, Zhengguo Li, Liangming Zhang, Xicheng Wang, Xueli Yuan, Tangfeng Lv, Yinghua Ji, Jian Fang, Guangyu An, Yueyin Pan, Lin Wu, Jiuwei Cui, Wei Zhang, Jianying Zhou, Xiaohong Wu, Qingshan Li, Jun Liang, Hui Luo, Huiwen Ma, Bangwei Cao, Jingchang Li, Rui Meng, Xi Chen, Fen Wang, Y Li, Yiping Zhang, Xiaoping Huang, Rui Ma, Zhiyong Ma, Yan Tan, Wen Li, Youlun Li, Na Li, Dongji Chen, Hui Zhao, Haixin Huang, Zhongyao Jia, Jun Chen, Jianhua Chang, Meili Sun, Youxin Ji, Zhitu Zhu, Aihong Zhong, Yarong Li, Liyan Jiang, Dongqing Lv, Mengzhao Wang, Wei Zhang, Ming Fan, Manxiang Li, Zhenping Wen, Haichuan Su, Diansheng Zhong, Min Ye · 发表于：The Lancet Respiratory Medicine · 年份：2025 · DOI：10.1016/s2213-2600(25)00263-2 · 被引用次数：7 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis